Several peptide therapeutics areused as replacement therapies in order to supplement peptide hormones whenendogenous levels are inadequate or absent. Insulin and adrenocorticotrophichormone (ACTH) are peptides isolated from natural sources, whereas oxytocin andvasopressin are synthetic peptides.
The global PeptideTherapeutics Market is estimated to account for US$ 23,319.3 Mn in terms ofvalue and is expected to reach US$ 57,166.5 Mn by the end of 2027.
Global Peptide TherapeuticsMarket: Drivers
Increasing adoption of peptidetherapeutics is expected to aid in growth of the global peptide therapeuticsmarket over the forecast period. Peptides therapeutics are typically associatedwith lower production complexity compared withprotein-based-biopharmaceuticals. This in turn results in lower productioncosts, which increases adoption of peptides therapeutics compared to small moleculesand biopharmaceuticals.
Global Peptide Therapeutics Market:Opportunities
Development of multifunctionalpeptides and conjugates is expected to offer lucrative growth opportunities forplayers in the market. For instance, in February 2019, researchers fromUniversity of Milan reported that the polypeptide lunasin derived from bioactivefood offered hypocholesterolemic, antioxidant, and anti-inflammatory propertiesand can be effective in prevention of cardiovascular disease.
Global Peptide TherapeuticsMarket: Restraints
Therapeutic peptides have lowmembrane permeability and are prone to hydrolysis and oxidation, which isexpected to hinder growth of the market.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1837
Key Takeaways:
The branded sub segment in theproduct type segment in global peptide therapeutics market was valued at US$12,415.2 Mn in 2018 and is expected to reach US$ 27,349.8 Mn by 2027 at a CAGRof 9.1% during the forecast period.
Branded medications in thepeptide therapeutics market have extensive patent protections and preferred bythe physicians in developed as well as emerging economies. Moreover, brandedmedications are costly as compared to generic peptide therapeutics.
The cancer sub segment inapplications segment held dominant position in the global peptide therapeuticsmarket in 2018, accounting for 34.3% share in terms of value, followed bymetabolic disorders and central nervous system disorders, respectively.
Increasing prevalence of canceris expected to create lucrative opportunities for growth of manufacturers inthe market. For instance, according to the National Cancer Institute, 2016, thenumber of new cancer cases per year is expected to increase to 23.6 million by2030, worldwide.
The parenteral sub segment inroute of administration segment held dominant position in the global peptidetherapeutics market in 20148, accounting for 70.4% share in terms of value,followed by transdermal route and mucosal route, respectively.
Vast number of parenteral peptidetherapeutics have been launched in the market. These drugs are effective as thedrug is directly administered in the blood stream bypassing gastrointestinaltract.
Market Trends
The market is witnessingincreasing adoption of peptide therapeutics for the treatment of cancer. Forinstance, in January 2020, IBicycle Therapeutics plc., a biotechnology thatdevelops therapeutics based on its proprietary bicyclic peptide technology,collaborated with Cancer Research UK for funding in R&D of BT7401, amultivalent Bicycle CD137 agonist for the treatment of cancer.
Major players in the market arefocused on collaborating with universities for R&D of new peptidetherapeutics. For instance, in 2018, Sapience Therapeutics, Inc., abiotechnology company focused on R&D in peptide therapeutics, collaboratedwith the University of Bath to discover new therapeutic agents.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/peptide-therapeutics-market-1837
Regulations
Europe
The medicines regulatoryauthorities of the Member States, or 'national competent authorities', areresponsible for the authorisation of medicines available in the EU that do notpass though the centralised procedure.
For clinical trials, EuropeanMedicines Agency maintains only EUDRACT and EUDRAVigilance database. TheNational agency of each country is responsible for conducting the trial.
CHMP or Committee for MedicinalProducts for Human use assess the product for marketing approval in EU
In EU, biologic is wide umbrellaterm that includes peptides
Non-clinical studies are carriedout according to ICH-S6 guidelines
There is a centralised MAAprocedure; however, biologics are also approved at member state level
Global Peptide TherapeuticsMarket: Competitive Landscape
Major players operating in theglobal peptide therapeutics market include, AstraZeneca plc., Bachem HoldingAG, CordenPharma International, Eli Lilly and Company, Ipsen S.A, Merck &Co., Inc., Novo Nordisk A/S, PolyPeptide Group, and Teva PharmaceuticalIndustries Ltd.
Global Peptide TherapeuticsMarket: Key Developments
January 2020: Cybrexa Therapeutics,a privately-held biotechnology company focused on development ofnext-generation tumor-targeted cancer therapies, announced CBX-12 (alphalexexatecan) as the new lead development program. The Cybrexa alphalex technologyplatform consists of a pHLIP peptide, linker, and small molecule anti-canceragent.
January 2020: ProtagonistTherapeutics, Inc. announced the achievement of a research milestone under itsworldwide license and research collaboration agreement with Janssen Biotech,Inc., for co-development and commercialization of PTG-200, an oral,gut-restricted IL-23 receptor antagonist and second generation peptides for thetreatment of inflammatory bowel disease.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1837
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
